GRFS Key Statistics, Chart & Performance
The current stock price of GRFS is 8.85 USD. In the past month the price increased by 5.86%. In the past year, price increased by 21.23%.
GRFS Latest News, Press Relases and Analysis
GRFS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About GRFS
Company Profile
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Company Info
GRIFOLS SA-ADR
Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158
Sant Cugat del Valles BARCELONA 08174 ES
CEO: Raimon Grifols Roura
Employees: 23833
Phone: 34935710000
GRIFOLS SA-ADR / GRFS FAQ
Can you describe the business of GRIFOLS SA-ADR?
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
What is the current price of GRFS stock?
The current stock price of GRFS is 8.85 USD. The price decreased by -0.45% in the last trading session.
Does GRFS stock pay dividends?
GRIFOLS SA-ADR (GRFS) has a dividend yield of 4.62%. The yearly dividend amount is currently 0.
What is the ChartMill rating of GRIFOLS SA-ADR stock?
GRFS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for GRFS stock?
The PE ratio for GRIFOLS SA-ADR (GRFS) is 17.02. This is based on the reported non-GAAP earnings per share of 0.52 and the current share price of 8.85 USD.
Is GRIFOLS SA-ADR (GRFS) expected to grow?
The Revenue of GRIFOLS SA-ADR (GRFS) is expected to grow by 5.31% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of GRIFOLS SA-ADR (GRFS) stock?
The outstanding short interest for GRIFOLS SA-ADR (GRFS) is 1.78% of its float.
GRFS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GRFS. When comparing the yearly performance of all stocks, GRFS turns out to be only a medium performer in the overall market: it outperformed 60.44% of all stocks.
GRFS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GRFS. While GRFS has a great profitability rating, there are some minor concerns on its financial health.
GRFS Financial Highlights
Over the last trailing twelve months GRFS reported a non-GAAP Earnings per Share(EPS) of 0.52. The EPS increased by 109.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.99% | ||
| ROA | 1.5% | ||
| ROE | 5.75% | ||
| Debt/Equity | 1.66 |
GRFS Forecast & Estimates
20 analysts have analysed GRFS and the average price target is 13.01 USD. This implies a price increase of 47.06% is expected in the next year compared to the current price of 8.85.
For the next year, analysts expect an EPS growth of 44.31% and a revenue growth 5.31% for GRFS